{"id":"F2020L01395","name":"Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020)","slug":"statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":130620,"registerId":"commonwealth-F2020L01395-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020)","content":"![Commonwealth Coat of Arms](image.001.png)\n\nStatement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020)\n\nmade under subsection 196B(2) of the\n\nVeterans' Entitlements Act 1986\n\nCompilation No. 1\n\nCompilation date: 19 September 2022\n\nIncludes amendments up to: Amendment Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 90 of 2022) (F2022L01130)\n\nThe day of commencement of this Amendment Statement of Principles concerning conjunctivitis is 19 September 2022.\n\nAbout this compilation\n\nThis compilation\n\nThis is a compilation of the Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020) that shows the text of the law as amended and in force on 19 September 2022.\n\nThe notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.\n\nUncommenced amendments\n\nThe effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.\n\nApplication, saving and transitional provisions for provisions and amendments\n\nIf the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.\n\nModifications\n\nIf the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.\n\nSelf‑repealing provisions\n\nIf a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.\n\nContents\n\n1 Name\n\n3 Authority\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\n  \n\n1 Name\n\nThis is the Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020).\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about conjunctivitis and death from conjunctivitis.\n\nMeaning of conjunctivitis\n\n(2) For the purposes of this Statement of Principles, conjunctivitis means inflammation of the conjunctiva and includes blepharoconjunctivitis and keratoconjunctivitis.\n\n(3) While conjunctivitis attracts ICD‑10‑AM code H10, H13.1, H13.2 or H16.2, in applying this Statement of Principles the meaning of conjunctivitis is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from conjunctivitis\n\n(5) For the purposes of this Statement of Principles, conjunctivitis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's conjunctivitis.\n\n> Note: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that conjunctivitis and death from conjunctivitis can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\n> Note: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting conjunctivitis or death from conjunctivitis with the circumstances of a person's relevant service:\n\n(1) having blepharitis of the affected eye at the time of the clinical onset of conjunctivitis;\n\n(2) having an infection of the conjunctiva of the affected eye at the time of the clinical onset of conjunctivitis;\n\n> Note: infection of the conjunctiva is defined in the Schedule 1 - Dictionary.\n\n(3) having a condition of the affected eye from the specified list of conditions at the time of the clinical onset of conjunctivitis;\n\n> Note: specified list of conditions is defined in the Schedule 1 - Dictionary.\n\n(4) having a condition that causes chronic lack of sufficient lubrication and moisture on the surface of the affected eye at the time of the clinical onset of conjunctivitis;\n\n> Note: Examples of conditions associated with a chronic lack of sufficient lubrication and moisture on the surface of the eye include dysfunctional tear syndrome, keratoconjunctivitis sicca and Sjögren syndrome.\n\n(5) having ocular or periocular exposure to an allergen within the 24 hours before the clinical onset of conjunctivitis;\n\n> Note: allergen is defined in the Schedule 1 - Dictionary.\n\n(5A) having a sensitising exposure to an allergen before the clinical onset of conjunctivitis;\n\nNote: sensitising exposure to an allergen is defined in the Schedule 1 – Dictionary.\n\n(6) having an autoimmune disease at the time of the clinical onset of conjunctivitis;\n\n(7) having graft versus host disease at the time of the clinical onset of conjunctivitis;\n\n(8) having diabetes mellitus at the time of the clinical onset of conjunctivitis;\n\n(9) having topical medication applied to the affected eye within the 48 hours before the clinical onset of conjunctivitis;\n\n(10) taking a drug from the specified list of drugs for at least the seven days before the clinical onset of conjunctivitis;\n\n> Note: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(11) taking a drug which is associated in the individual with the development of conjunctivitis during drug therapy and either:\n\n(a) the improvement of conjunctivitis within seven days of discontinuing or tapering drug therapy; or\n\n(b) the redevelopment of conjunctivitis on rechallenge with the same drug;\n\nwhere treatment with the drug continued for at least the seven days before the clinical onset of conjunctivitis;\n\n(12) having ocular or periocular exposure to an irritant substance within the 24 hours before the clinical onset of conjunctivitis;\n\n> Note: irritant substance is defined in the Schedule 1 - Dictionary.\n\n(13) having mustard gas exposure to the affected eye within the 24 hours before the clinical onset of conjunctivitis;\n\n(14) having a foreign body in contact with the affected conjunctiva within the 24 hours before the clinical onset of conjunctivitis;\n\n(15) having an injury to the conjunctiva of the affected eye within the 24 hours before the clinical onset of conjunctivitis;\n\n> Note: injury to the conjunctiva is defined in the Schedule 1 - Dictionary.\n\n(16) undergoing a course of therapeutic radiation for cancer, where the region of the affected eye was in the field of radiation, at the time of the clinical onset of conjunctivitis;\n\n(17) having a benign or malignant neoplasm affecting the conjunctiva or eyelid margin of the affected eye at the time of the clinical onset of conjunctivitis;\n\n(18) being in an immunocompromised state as specified at the time of the clinical onset of conjunctivitis;\n\n> Note: immunocompromised state as specified is defined in the Schedule 1 - Dictionary.\n\n(19) having blepharitis of the affected eye at the time of the clinical worsening of conjunctivitis;\n\n(20) having an infection of the conjunctiva of the affected eye at the time of the clinical worsening of conjunctivitis;\n\n> Note: infection of the conjunctiva is defined in the Schedule 1 - Dictionary.\n\n(21) having a condition of the affected eye from the specified list of conditions at the time of the clinical worsening of conjunctivitis;\n\n> Note: specified list of conditions is defined in the Schedule 1 - Dictionary.\n\n(22) having a condition that causes chronic lack of sufficient lubrication and moisture on the surface of the affected eye at the time of the clinical worsening of conjunctivitis;\n\n> Note: Examples of conditions associated with a chronic lack of sufficient lubrication and moisture on the surface of the eye include dysfunctional tear syndrome, keratoconjunctivitis sicca and Sjögren syndrome.\n\n(23) having ocular or periocular exposure to an allergen within the 24 hours before the clinical worsening of conjunctivitis;\n\n> Note: allergen is defined in the Schedule 1 - Dictionary.\n\n(24) having an autoimmune disease at the time of the clinical worsening of conjunctivitis;\n\n(25) having graft versus host disease at the time of the clinical worsening of conjunctivitis;\n\n(26) having diabetes mellitus at the time of the clinical worsening of conjunctivitis;\n\n(27) having topical medication applied to the affected eye within the 48 hours before the clinical worsening of conjunctivitis;\n\n(28) taking a drug from the specified list of drugs for at least the seven days before the clinical worsening of conjunctivitis;\n\n> Note: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(29) taking a drug which is associated in the individual with:\n\n(a) the worsening of conjunctivitis during drug therapy; and\n\n(b) the improvement of conjunctivitis within seven days of discontinuing or tapering drug therapy;\n\nwhere treatment with the drug continued for at least the seven days before the clinical worsening of conjunctivitis;\n\n(30) having ocular or periocular exposure to an irritant substance within the 24 hours before the clinical worsening of conjunctivitis;\n\n> Note: irritant substance is defined in the Schedule 1 - Dictionary.\n\n(31) having mustard gas exposure to the affected eye within the 24 hours before the clinical worsening of conjunctivitis;\n\n(32) having a foreign body in contact with the affected conjunctiva within the 24 hours before the clinical worsening of conjunctivitis;\n\n(33) having an injury to the conjunctiva of the affected eye within the 24 hours before the clinical worsening of conjunctivitis;\n\n> Note: injury to the conjunctiva is defined in the Schedule 1 - Dictionary.\n\n(34) undergoing a course of therapeutic radiation for cancer, where the region of the affected eye was in the field of radiation, at the time of the clinical worsening of conjunctivitis;\n\n(35) having a benign or malignant neoplasm affecting the conjunctiva or eyelid margin of the affected eye at the time of the clinical worsening of conjunctivitis;\n\n(36) being in an immunocompromised state as specified at the time of the clinical worsening of conjunctivitis;\n\n> Note: immunocompromised state as specified is defined in the Schedule 1 - Dictionary.\n\n(37) inability to obtain appropriate clinical management for conjunctivitis.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(19) to 9(37) apply only to material contribution to, or aggravation of, conjunctivitis where the person's conjunctivitis was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\nSchedule 1 \\- Dictionary\n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\nallergen means an antigenic substance capable of producing an immune response.\n\nchronic renal failure means:\n\n(a) having a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least three months; or\n\n(b) a need for renal replacement therapy (dialysis or transplantation) for treatment of complications of decreased glomerular filtration rate which would otherwise increase the risk of morbidity and mortality; or\n\n(c) undergoing chronic dialysis.\n\nconjunctivitis—see subsection 7(2).\n\nimmunocompromised state as specified means a condition of substantially lowered immune function, such as would occur in the following conditions or circumstances:\n\n(a) taking an immunosuppressive drug;\n\n(b) having a haematological or solid organ malignancy;\n\n(c) having chronic renal failure;\n\n(d) having infection with human immunodeficiency virus;\n\n(e) having severe malnutrition; or\n\n(f) undergoing solid organ, stem cell or bone marrow transplantation.\n\n> Note: chronic renal failure and immunosuppressive drug are also defined in the Schedule 1 \\- Dictionary.\n\nimmunosuppressive drug means a drug or an agent which results in substantial suppression of immune responses.\n\n> Note: Examples of an immunosuppressive drug include:\n\n> Note: (a) chemotherapeutic agents used for the treatment of cancer;\n\n> Note: (b) corticosteroids, other than inhaled or topical corticosteroids;\n\n> Note: (c) drugs used to prevent transplant rejection; or\n\n> Note: (d) a tumour necrosis factor-alpha inhibitor.\n\ninfection of the conjunctiva means a bacterial, viral, rickettsial, parasitic or fungal infection involving the conjunctiva.\n\ninjury to the conjunctiva means trauma to the ocular surface involving the conjunctiva by mechanisms including thermal, electrical and chemical burns and blunt or penetrating trauma.\n\nirritant substance means a chemical which causes an inflammatory effect on living tissue by chemical action at the site of contact.\n\nMRCA means the Military Rehabilitation and Compensation Act 2004.\n\nrelevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\n> Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\nsensitising exposure to an allergen means an exposure to an allergen without the occurrence of symptoms, where the clinical onset of conjunctivitis occurs within the two weeks of a subsequent exposure to the same allergen.\n\n> Note: The initial sensitising exposure to an allergen may be either systemic or cutaneous and may have occurred months to years before the re-exposure that has resulted in the conjunctivitis.\n\nspecified list of conditions means:\n\n(a) disorder of nasolacrimal duct or gland;\n\n(b) ectropion;\n\n(c) exophthalmos; or\n\n(d) lid retraction.\n\nspecified list of drugs means:\n\n(a) benzodiazepines;\n\n(b) bisphosphonates;\n\n(c) celecoxib;\n\n(d) chemotherapy for cancer;\n\n(e) cyclosporine;\n\n(f) dupilumab;\n\n(g) fluoxetine;\n\n(h) imatinib;\n\n(i) isotretinoin;\n\n(j) paroxetine;\n\n(k) risperidone;\n\n(l) tadalafil;\n\n(m) topiramate;\n\n(n) vardenafil; or\n\n(o) vemurafenib.\n\nterminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\nVEA means the Veterans' Entitlements Act 1986.\n\n> Note: Endnotes\n\n> Note: Endnote 1—About the endnotes\n\nThe endnotes provide information about this compilation and the compiled law.\n\nThe following endnotes are included in every compilation:\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\nAbbreviation key—Endnote 2\n\nThe abbreviation key sets out abbreviations that may be used in the endnotes.\n\nLegislation history and amendment history—Endnotes 3 and 4\n\nAmending laws are annotated in the legislation history and amendment history.\n\nThe legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.\n\nThe amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.\n\nMisdescribed amendments\n\nA misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.\n\nIf a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.\n\n> Note: Endnote 2—Abbreviation key\n\n|                                                | o = order(s)                        |\n| ---------------------------------------------- | ----------------------------------- |\n| ad = added or inserted                         | Ord = Ordinance                     |\n| am = amended                                   | orig = original                     |\n| amdt = amendment                               | par = paragraph(s)/subparagraph(s)  |\n| c = clause(s)                                  | /sub‑subparagraph(s)                |\n| C[x] = Compilation No. x                       | pres = present                      |\n| Ch = Chapter(s)                                | prev = previous                     |\n| def = definition(s)                            | (prev…) = previously                |\n| Dict = Dictionary                              | Pt = Part(s)                        |\n| disallowed = disallowed by Parliament          | r = regulation(s)/rule(s)           |\n| Div = Division(s)                              |                                     |\n| exp = expires/expired or ceases/ceased to have | reloc = relocated                   |\n| effect                                         | renum = renumbered                  |\n| F = Federal Register of Legislation            | rep = repealed                      |\n| gaz = gazette                                  | rs = repealed and substituted       |\n| LA = Legislation Act 2003                      | s = section(s)/subsection(s)        |\n| LIA = Legislative Instruments Act 2003         | Sch = Schedule(s)                   |\n| (md) = misdescribed amendment can be given     | Sdiv = Subdivision(s)               |\n| effect                                         | SLI = Select Legislative Instrument |\n| (md not incorp) = misdescribed amendment       | SR = Statutory Rules                |\n| cannot be given effect                         | Sub‑Ch = Sub‑Chapter(s)             |\n| mod = modified/modification                    | SubPt = Subpart(s)                  |\n| No. = Number(s)                                | underlining = whole or part not     |\n|                                                | commenced or to be commenced        |\n\n> Note: Endnote 3—Legislation history\n\n| Name                                                                                                 | Registration               | Commencement      | Application, saving and transitional provisions |\n| ---------------------------------------------------------------------------------------------------- | -------------------------- | ----------------- | ----------------------------------------------- |\n| Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 76 of 2020)           | 2 November 2020F2020L01395 | 30 November 2020  |                                                 |\n| Amendment Statement of Principles concerning conjunctivitis (Reasonable Hypothesis) (No. 90 of 2022) | 29 August 2022F2022L01130  | 19 September 2022 |                                                 |\n\n> Note: Endnote 4—Amendment history\n\n| Provision affected                                                  | How affected      |\n| ------------------------------------------------------------------- | ----------------- |\n| Section 2……………….                                                    | rep LA s 48D      |\n| Section 4……………….                                                    | rep LA s 48C      |\n| Subsection 9(5A)………                                                 | ad No. 90 of 2022 |\n| Schedule 1 – Dictionary – sensitising exposure to an allergen………….. | ad No. 90 of 2022 |","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"The legislation maintains its original narrow scope. It was always intended to provide detailed medical criteria specifically for conjunctivitis in the veterans' compensation context. The 2022 amendment added one new factor (9(5A)) and one new definition regarding allergen sensitisation, but this represents a minor technical update rather than scope creep. The instrument remains tightly focused on its original purpose: establishing service connection for a single eye condition."},"complexity_factors":["Straightforward list structure with 37 numbered factors, but significant duplication (factors 1-18 for 'clinical onset' mirror factors 19-36 for 'clinical worsening' with minor variations)","19 defined terms in Schedule 1 Dictionary, including nested definitions (e.g., 'immunocompromised state as specified' refers to 'chronic renal failure' and 'immunosuppressive drug', which have their own definitions)","Cross-references to external legislation (VEA and MRCA) and medical classification systems (ICD-10-AM Tenth Edition)","Conditional logic in factor 11 requiring a three-part drug reaction test (association + improvement on discontinuation + rechallenge or 7-day minimum use)","Incorporation by reference of other Statements of Principles (section 11), meaning the full legal effect depends on unspecified external instruments","Temporal precision requirements (24-hour, 48-hour, 7-day windows; 'at the time of' vs 'within' timeframes)","Medical terminology requiring specialist knowledge (blepharoconjunctivitis, keratoconjunctivitis sicca, rickettsial infections, TNF-alpha inhibitors)"],"plain_english_summary":"This Statement of Principles sets the medical rules for deciding whether conjunctivitis (\"pink eye\") in current or former Australian Defence Force members is connected to service. It lists 37 medical factors — if at least one applies and relates to service, a \"reasonable hypothesis\" exists, making the veteran eligible for benefits under the Veterans' Entitlements Act 1986 or the Military Rehabilitation and Compensation Act 2004.\n\nIt matters because it lowers the proof threshold for access to treatment and compensation; it was updated in Sept 2022 to add allergen‑sensitisation factors."},"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"The instrument’s scope was expanded by Amendment No. 90 of 2022 to add a new factor—‘sensitising exposure to an allergen’—in subsection 9(5A) and to add a corresponding definition in Schedule 1. This increases the enumerated pathways by which conjunctivitis may be linked to service (see amendment entries and subsection 9(5A) and Schedule 1 additions noted in the compilation endnotes)."},"complexity_factors":["Large enumerated set of clinical and exposure factors (37+ specific items in section 9) that must be considered when assessing a claim, increasing factual complexity (s9).","Multiple medically technical distinctions—clinical onset versus clinical worsening—create timing-dependent causal rules that require precise medical evidence (s9, s10(2)).","Extensive defined terms and cross-references in the Schedule (allergen, infection of the conjunctiva, immunocompromised state, specified drugs/conditions) mean assessors must interpret medical definitions rather than plain language (Schedule 1).","Cross-reference to ICD-10-AM codes and external publication for disease codes requires familiarity with diagnostic coding standards (s7(3)-(4)).","Requirement that any listed factor be related to the person’s relevant service adds a legal causation layer — proof must link factor to service types defined in the instrument (s10(1); Schedule 1 definition of relevant service).","Interaction with other Statements of Principles lets other instruments override or supplement factors, producing inter-instrument dependency and potential conflicts (s11).","The Repatriation Medical Authority’s evidentiary standard is a ‘reasonable hypothesis’ (s8), which is lower than proof on balance but still requires documented clinical evidence—raising evidentiary and administrative burden on claimants and medical providers.","Specific drug list and examples (Schedule 1) and the addition of sensitising allergen exposure (s9(5A) and Schedule change) mean assessors must track evolving medical lists and amendments."],"plain_english_summary":"This Statement of Principles sets the medical criteria the Repatriation Medical Authority uses to decide whether a veteran's conjunctivitis (or death from it) can reasonably be linked to relevant service for VEA/MRCA claims. It lists clinical risk factors, exposures and timing distinctions (onset versus worsening) which, if present and related to service, raise a “reasonable hypothesis” of service connection.\n\nIt affects veterans and service members claiming entitlements; claimants must supply clinical evidence tied to the listed factors (for example infections, allergens, specified drugs, radiation or immunocompromise), and the instrument cross‑references medical codes and other Statements of Principles that affect evidentiary needs."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020","history":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020/history","analysis":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020/analysis","conflicts":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020/important-cases","documents":"/api/acts/statement-of-principles-concerning-conjunctivitis-reasonable-hypothesis-no-76-of-2020/documents"}}